Last reviewed · How we verify
NCT07258797: SHOOL
Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
NA trial testing SCRT : 25 Gy in 5 fractions over 1 week to the pelvis using IGRT technique in Adenocarcinoma of the Rectum in 150 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Rajiv Gandhi Cancer Institute & Research Center, India |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 1 December 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 March 2029 |
| Sites | 1 location across India |
Drugs / interventions tested
- SCRT : 25 Gy in 5 fractions over 1 week to the pelvis using IGRT technique
- LCRT + Consolidation Chemotherapy
Conditions studied
- Adenocarcinoma of the Rectum — all drugs for Adenocarcinoma of the Rectum →
Sponsor
Rajiv Gandhi Cancer Institute & Research Center, India
Who can join
Adults 18 to 75, any sex, with Adenocarcinoma of the Rectum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study compares two standard radiotherapy approaches (short-course vs. long-course) given before surgery in patients with locally advanced rectal cancer. The goal is to see which treatment is more effective and better tolerated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07258797
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adenocarcinoma of the Rectum
Currently open trials in the same condition.
- NCT06637462 — A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer · NA · recruiting
- NCT05672524 — A Study of Tucatinib and Trastuzumab in People With Rectal Cancer · Phase 2 · recruiting
- NCT04624555 — The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors · recruiting
- NCT05080673 — Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps · NA · recruiting
- NCT04668872 — Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation · recruiting
Other Rajiv Gandhi Cancer Institute & Research Center, India trials
Trials by the same sponsor.
- NCT06026475 — Role of Goal Directed Fluid Therapy in Enhanced Recovery After Surgery in Gastro-intestinal Oncosurgeries · NA · completed
- NCT05439109 — Correct Endotracheal Tube Placement Using Topographical Landmarks · NA · unknown
- NCT05721391 — Impact of Frailty on Postoperative Complications in Oncosurgery · completed
- NCT05142163 — Stroke Volume Variation and Plethysmography Variability Index as Goal Directed Fluid Therapy in Major Oncosurgeries · NA · completed
- NCT05038501 — Prevalence of Comorbidities in Patients Undergoing Oncosurgeries at Tertiary Cancer Institute in North India. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07258797 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rajiv Gandhi Cancer Institute & Research Center, India
- Last refreshed: 2 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07258797.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing